^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | 4-hydroxytestosterone transdermal (CR 1477) (Androgen receptor agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Final Overall Survival (OS) analysis of the SAKK 21/12 trial. CR1447 in HR+/HER2- metastatic breast cancer and androgen receptor positive triple negative breast cancer.
Published date:
12/02/2023
Excerpt:
In cohort A (ER+/HER2-negative metastatic disease)…Median OS for cohort A was 35.4 months (95% CI: 24.6-49.1) in the ITT population and 19.4 months (95% CI: 2.3-36.8) in the non-ITT population (patients with more than one line of endocrine therapy). In cohort B, median OS was 10.8 months (95% CI: 3.3-28.6).